(Press-News.org) LOS ANGELES (STRICTLY EMBARGOED UNTIL 7:30 A.M. EDT on JUNE 1, 2014 - ASCO Abstract No. 2005) – A multicenter team of investigators, led by researchers from the Cedars-Sinai Department of Neurosurgery, the Cedars-Sinai Maxine Dunitz Neurosurgical Institute and Dana-Farber Cancer Institute in Boston, have found in a Phase II clinical trial that an immune system-boosting therapy slowed the recurrence of glioblastoma multiforme, or GBM, the most common and deadly malignant brain tumor.
They will present their findings in an oral presentation June 1 at the annual meeting of the American Society of Clinical Oncology in Chicago.
The study included 124 newly diagnosed patients at 25 clinical trial sites in the U.S. Two-thirds of the patients were treated with ICT-107, an experimental vaccine based on immune system cells called dendritic cells that were exposed to six synthetic proteins, or antigens, known to be involved in GBM development. Immunization is intended to stimulate the immune system to detect and fight cancer cells. The remaining one-third of patients, composing a control group, received injections of their own dendritic cells that were not exposed to tumor antigens. All patients also were given standard care, including surgical tumor removal, chemotherapy and radiation therapy.
Of the 124 patients, 117 were able to participate according to study protocol, which included four initial treatments with ICT-107 followed by periodic maintenance doses. The trial was designed to evaluate overall survival statistics and progression-free survival – the period of time between initial treatment and tumor recurrence. Glioblastomas are so aggressive and resistant to treatment, they usually return within months of surgical removal, despite standard treatments.
In the most recent results of the trial, treatment increased median overall survival by two months in patients treated according to protocol. This did not reach statistical significance, in part, researchers believe, because follow-up time has been relatively short; 45 patients remain alive for further assessment. Median progression-free survival, which increased by three months in patients receiving therapy, was statistically significant.
"This trial had two major findings. First, the time until a patient's tumor progressed was significantly extended in patients that received the vaccine therapy. The quality of life of these patients was maintained longer as well as their performance score, and they needed steroids less frequently than non-vaccinated patients. Second, we believe the vaccine may be particularly beneficial for a group of patients with the HLA-A2 type, which suggests that as we move forward, there may be advantages in targeting this population," said John Yu, MD, vice chair of the Department of Neurosurgery, director of surgical neuro-oncology, medical director of the Brain Tumor Center and neurosurgical director of the Gamma Knife Program at Cedars-Sinai. He is the abstract's senior author.
Among subgroup analyses, the study evaluated patients' human lymphocyte antigen type, whether HLA-A1 or HLA-A2. HLA categorization is used to designate genetics related to immune cells. About 60 percent of those in the trial, as in the general population, were identified as HLA-A2 patients. The researchers said HLA-A2 patients treated with ICT-107 appeared to have increased overall survival, compared to those with HLA-A1.
Among key subgroup analysis focused on variations of a gene – O-6-methylguanine-DNA methyltransferase, or MGMT – that can affect a patient's response to treatment. Glioblastoma cells with "unmethylated" MGMT tend to be less responsive to chemotherapy and radiation than those that are "methylated."
In patients with HLA-A2 and unmethylated MGMT, those in the control group had a median overall survival of about 12 months, compared with about 16 months in the treatment group. Median progression-free survival improved by 4.5 months, from about six months in the control group to about 10.5 months among those treated.
In patients with HLA-A2 and methylated MGMT, neither the control group nor the treatment group has reached a median survival point to date. However, median progression-free survival is statistically significant, with the control group at about 8.6 months and the treatment group at 24.5 months – a 16-month advantage for the ICT-107 group.
"This is the first placebo-controlled, randomized study of a vaccine for glioblastoma to show a significant benefit in a clinically meaningful endpoint, progression-free survival. In addition, the subgroup of patients with unmethylated MGMT promoter and HLA-A2 appear to particularly benefit," said Patrick Y. Wen, MD, director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute and professor of Neurology, Harvard Medical School, who will present the data at the conference. He is the abstract's first author.
ICT-107 is a product of the biotechnology company ImmunoCellular Therapeutics Ltd. John S. Yu, MD, vice chair of the Department of Neurosurgery, director of the Brain Tumor Center, director of Surgical Neuro-Oncology and surgical director of the Gamma Knife Center at Cedars-Sinai, is founder, chief scientific officer and chairman of the board. Yu is a salaried employee of the company and owns stock in it. Dendritic cell immunotherapy for GBM was first used in experimental treatment at Cedars-Sinai in 1998. Certain rights in the vaccine technology and corresponding intellectual property have been exclusively licensed by Cedars-Sinai to ImmunoCellular Therapeutics, including subsequently developed versions of the vaccine investigated in this clinical study. Cedars-Sinai also owns stock in the company.
Twenty authors, including Surasak Phuphanich, director of Cedar-Sinai's Neuro-Oncology Program, contributed to this study. One author is affiliated with ImmunoCellular Therapeutics as a consultant or adviser; one receives research funding from the company; one receives honoraria and serves in an advisory or consultant role to a company called Stemline Therapeutics; one receives honoraria from Merck. No other authors report disclosures or potential conflicts of interest.
INFORMATION:
Dana-Farber Cancer Institute, a principal teaching affiliate of Harvard Medical School, is world-renowned for its leadership in adult and pediatric cancer treatment and research. Designated as a comprehensive cancer center by the National Cancer Institute (NCI), it is one of the largest recipients among independent hospitals of NCI and National Institutes of Health grant funding. For more information, go to http://www.dana-farber.org.
Citation: Oral presentation June 1 at American Society of Clinical Oncology annual meeting: "A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma patients."
(EMBARGOED UNTIL 7:30 A.M. EDT on JUNE 1, 2014)
Researchers to provide update on Phase II trial of vaccine for malignant brain tumors
Authors of American Society of Clinical Oncology abstract say certain patient subgroups appear to see greater benefit, suggesting future studies may target those populations
2014-06-02
ELSE PRESS RELEASES FROM THIS DATE:
Major advances in breast, prostate, colorectal cancer featured at ASCO Annual Meeting
2014-06-02
CHICAGO – Findings from four phase III clinical trials in breast, prostate, and colorectal cancers were released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). The studies were presented in ASCO's Plenary session, which features the meeting's most important clinical cancer research with the greatest potential to impact patient care.
These pivotal studies reveal new ways to optimize commonly used chemotherapy, hormone therapies, and newer targeted drugs, and answer critical questions about the comparative effectiveness of two common ...
World's best thermometer made from light
2014-06-02
University of Adelaide physics researchers have produced the world's most sensitive thermometer – three times more precise than the best thermometers in existence.
Published in the journal Physical Review Letters, the researchers from the University's Institute for Photonics and Advanced Sensing (IPAS) report they have been able to measure temperature with a precision of 30 billionths of a degree.
"We believe this is the best measurement ever made of temperature − at room temperature," says project leader Professor Andre Luiten, Chair of Experimental Physics in ...
Breakthrough in energy storage: Electrical cables that can store energy
2014-06-02
VIDEO:
Dr. Thomas and his team light an LED using energy stored in the outside coatings of an electrical cable.
Click here for more information.
Imagine being able to carry all the juice you needed to power your MP3 player, smartphone and electric car in the fabric of your jacket?
Sounds like science fiction, but it may become a reality thanks to breakthrough technology developed at a University of Central Florida research lab.
So far electrical cables are used only to transmit ...
Common cholesterol drug greatly alters inflammatory response to common cold
2014-06-02
Cold season may be just behind us, but a new discovery may shed light on how this common condition triggers asthma attacks. In a new research report published in the June 2014 issue of the Journal of Leukocyte Biology, researchers show that in individuals with asthma, statins significantly reduce the in vitro inflammatory response of human monocytes to rhinovirus (RV), the cause of the common cold. Not only does this discovery suggest that statins could help prevent or reduce the severity of asthma symptoms resulting from colds, but may also open the doors to further research ...
Why some experimental forms of 'The Pill for Males' will never rise to the occasion
2014-06-02
It appears that "The Pill" for men will have to wait a while longer. A new research report published in the June 2014 issue of The FASEB Journal involving mice, shows that a previously developed male hormonal oral contraceptive method (i.e. via testosterone) is unable to stop the production and / or the release of sperm.
"Our research in mice explains why the efficacy of male hormonal contraception is not as effective as expected and it provides clues on how to improve the method," said Ilpo Huhtaniemi, M.D., Ph.D., M.D.hc, FMed.Sci., a researcher involved in the work ...
Early steps toward personalized fitness: Interval training may benefit men more than women
2014-06-02
When it comes to reaping benefits of sprint interval training, it appears that men have won the battle of the sexes, if just barely. According to new research published in the June 2014 issue of The FASEB Journal, men create more new proteins as a result of this exercise than women do. The good news, however, is that men and women experienced similar increases in aerobic capacity. This study is the first to directly measure the creation of proteins made to adapt to this mode of exercise. The study also uniquely used methods that measure the cumulative making of proteins ...
Nano-platform ready: Scientists use DNA origami to create 2D structures
2014-06-02
Scientists at New York University and the University of Melbourne have developed a method using DNA origami to turn one-dimensional nano materials into two dimensions. Their breakthrough, published in the latest issue of the journal Nature Nanotechnology, offers the potential to enhance fiber optics and electronic devices by reducing their size and increasing their speed.
"We can now take linear nano-materials and direct how they are organized in two dimensions, using a DNA origami platform to create any number of shapes," explains NYU Chemistry Professor Nadrian Seeman, ...
Study finds that suicides are far more likely to occur after midnight
2014-06-02
DARIEN, IL – A new study provides novel evidence suggesting that suicides are far more likely to occur between midnight and 4 a.m. than during the daytime or evening.
Results show that the weighted, scaled mean suicide rate per hour was 10.27 percent after midnight, peaking at 16.27 percent between 2 a.m. and 2:59 a.m. In contrast, the mean suicide rate per hour was 2.13 percent between 6 a.m. and 11:59 p.m. When six-hour time blocks were examined, the observed frequency of suicide between midnight and 5:59 a.m. was 3.6 times higher than expected.
"This appears to ...
Antipsychotic medication during pregnancy does affect babies, study shows
2014-06-02
A seven-year study of women who take antipsychotic medication while pregnant, proves it can affect babies.
The observational study, published in the journal PLOS ONE, reveals that whilst most women gave birth to healthy babies, the use of mood stabilisers or higher doses of antipsychotics during pregnancy increased the need for special care after birth with 43 per cent of babies placed in a Special Care Nursery (SCN) or a Neonatal Intensive Care Unit (NICU), almost three times the national rate in Australia.
As well as an increased likelihood of the need for intensive ...
Neuron tells stem cells to grow new neurons
2014-06-02
DURHAM, N.C. -- Duke researchers have found a new type of neuron in the adult brain that is capable of telling stem cells to make more new neurons. Though the experiments are in their early stages, the finding opens the tantalizing possibility that the brain may be able to repair itself from within.
Neuroscientists have suspected for some time that the brain has some capacity to direct the manufacturing of new neurons, but it was difficult to determine where these instructions are coming from, explains Chay Kuo, M.D. Ph.D., an assistant professor of cell biology, neurobiology ...
LAST 30 PRESS RELEASES:
Program takes aim at drinking, unsafe sex, and sexual assault on college campuses
Inability to pay for healthcare reaches record high in U.S.
Science ‘storytelling’ urgently needed amid climate and biodiversity crisis
KAIST Develops Retinal Therapy to Restore Lost Vision
Adipocyte-hepatocyte signaling mechanism uncovered in endoplasmic reticulum stress response
Mammals were adapting from life in the trees to living on the ground before dinosaur-killing asteroid
Low LDL cholesterol levels linked to reduced risk of dementia
Thickening of the eye’s retina associated with greater risk and severity of postoperative delirium in older patients
Almost one in ten people surveyed report having been harmed by the NHS in the last three years
Enhancing light control with complex frequency excitations
New research finds novel drug target for acute myeloid leukemia, bringing hope for cancer patients
New insight into factors associated with a common disease among dogs and humans
Illuminating single atoms for sustainable propylene production
New study finds Rocky Mountain snow contamination
Study examines lactation in critically ill patients
UVA Engineering Dean Jennifer West earns AIMBE’s 2025 Pierre Galletti Award
Doubling down on metasurfaces
New Cedars-Sinai study shows how specialized diet can improve gut disorders
Making moves and hitting the breaks: Owl journeys surprise researchers in western Montana
PKU Scientists simulate the origin and evolution of the North Atlantic Oscillation
ICRAFT breakthrough: Unlocking A20’s dual role in cancer immunotherapy
How VR technology is changing the game for Alzheimer’s disease
A borrowed bacterial gene allowed some marine diatoms to live on a seaweed diet
Balance between two competing nerve proteins deters symptoms of autism in mice
Use of antifungals in agriculture may increase resistance in an infectious yeast
Awareness grows of cancer risk from alcohol consumption, survey finds
The experts that can outsmart optical illusions
Pregnancy may reduce long COVID risk
Scientists uncover novel immune mechanism in wheat tandem kinase
Three University of Virginia Engineering faculty elected as AAAS Fellows
[Press-News.org] Researchers to provide update on Phase II trial of vaccine for malignant brain tumorsAuthors of American Society of Clinical Oncology abstract say certain patient subgroups appear to see greater benefit, suggesting future studies may target those populations